Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14535437 | 0.84 | HTT (0.71) | HTTALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL7897298 | 0.84 | SMN1; SMN2 (0.69) | HTTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL28167867 | 0.84 | ALDH1A1 (0.64) | HTTALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL28167869 | 0.84 | ALDH1A1 (0.64) | HTTALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL19658757 | 0.84 | HTT (0.71) | HTTALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL16225107 | 0.83 | GPR139 (0.51) | HTTALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1153625 | 0.83 | HTT (0.60) | HTTALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL2938094 | 0.82 | ALDH1A1 (0.66) | HTTALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL3838394 | 0.82 | ALDH1A1 (0.66) | HTTALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL2938096 | 0.82 | ALDH1A1 (0.66) | HTTALDH1A1LMNASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | HTT 2557/4885ALDH1A1 245/4885KDM4E 2975/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | HTT 2259/4885ALDH1A1 281/4885KDM4E 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.